Active Biotech AB

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Merck KGaA Pays $600m For Transfection

Scrip regularly reviews technology transfer activity across the biopharmaceutical sector. Recent editions of Tech Transfer Roundup focused on oncology and COVID-19 deals. This reviews the rest of

Vaccinex, Inc. ’s potentially disease-modifying therapy for Huntington’s disease missed its key endpoints in top-line data unveiled 22 September from the Phase II SIGNAL study, but the biotech thinks

Revolution Medicines Inc. continued this year’s biopharmaceutical initial public offering trend by closing well above its IPO price on its first day of trading. In fact, investors have been so intrig